Abstract 1088: LiverSCA 2.0: An enhanced and comprehensive cell atlas of human hepatocellular carcinoma, intrahepatic cholangiocarcinoma and metabolic dysfunction-associated steatotic liver disease/steatohepatitis

Abstract Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two distinct types of primary liver cancer (PLC) characterized by a considerable degree of cellular and molecular heterogeneity. We recently developed a web-based cell atlas called LiverSCA with a user-friendly interface, comprehensive functionality, and a complete set of analytical pipelines. In the previous version, LiverSCA includes 40 subjects (35 HCC patients with various etiological risk factors and five healthy controls) with a total cell count of more than 140, 000 cells. It facilitates the exploration of gene expression patterns, cellular composition, and intercellular communication in the liver and PLC tumor microenvironment, aiming to help researchers discover new mechanistic insights into the complex tumor microenvironment of HCC. To further enhance the comprehensiveness of LiverSCA, we have expanded its catalog with additional datasets of different phenotypes/subtypes of liver and PLC, such as intrahepatic cholangiocarcinoma (ICC) and metabolic dysfunction-associated fatty liver disease/steatosis (MASLD/MASH). The current enhanced version of the LiverSCA cell atlas contains six phenotypes (normal, HBV-HCC, HCV-HCC, non-viral HCC, ICC, and MASH), encompassing 63 patients and more than 248, 000 cells. In addition, we have incorporated a comparative visualization method that allows users to simultaneously examine and compare gene expression levels between two different phenotypes. We are committed to the continued development of LiverSCA to narrow the knowledge gap between different research fields and accelerate knowledge transfer in the scientific community. We envision that it will become a valuable resource that supports researchers to conveniently study the cellular and molecular landscape of the liver and PLCs. In addition, as scRNA-seq technology is still rapidly evolving, more features, such as spatial transcriptomics and multimodal omics, will be considered in future updates. Citation Format: Fanhong Zeng, Renwen Long, Tina Suoangbaj, Irene Oi-Lin Ng, Daniel Wai-Hung Ho. LiverSCA 2.0: An enhanced and comprehensive cell atlas of human hepatocellular carcinoma, intrahepatic cholangiocarcinoma and metabolic dysfunction-associated steatotic liver disease/steatohepatitis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1088.